跳到正文
原文
MedPage Today·· 2 天前AI 评分56

FDA拟撤销液态辛伐他汀FloLipid上市许可

FDA Wants Liquid Statin Off Shelves

AI 导读

FDA在联邦公报发布通知,要求液态辛伐他汀口服混悬液FloLipid撤市,原因是生产商Salerno Pharma屡次未按规定提交年度报告。FDA正在给予企业申请听证的机会以申辩保留批准。

正文

— Missing annual reports put simvastatin oral suspension on thin ice

by Nicole Lou, Senior Staff Writer, MedPage Today

November 17, 2026 • 2 min read

The FDA wants a liquid formulation of simvastatin (FloLipid) withdrawn from the market, though the agency is giving the drugmaker an opportunity for a hearing.

Approval of simvastatin oral suspension is at risk because Salerno Pharma "has repeatedly failed to file required annual reports" to the FDA, according to a notice in the Federal Register.

According to FDA policy, these annual reports are supposed to convey labeling information and technicalities, such as a current list of approved chemistry, manufacturing, and control information.

Initially approved in 2016 for a host of indications, simvastatin oral suspension is marketed as the first LDL cholesterol medication in liquid form for U.S. patients. The product was developed for patients who have difficulty swallowing pills, and the recommended usual starting dose is 10 mg or 20 mg once a day in the evening on an empty stomach.

Regarding safety, an increased risk of myopathy, including rhabdomyolysis, has been observed in patients taking an 80-mg dose of the oral suspension. Other patients unable to hit their LDL cholesterol goal taking the 40-mg dose are advised to initiate alternative LDL cholesterol-lowering treatments. In 2020, the drug label for the liquid simvastatin formulation was updated with a warning of rare reports of immune-mediated necrotizing myopathy associated with statin use.

According to the Federal Register notice -- which came from Michael Davis, MD, PhD, the FDA's top drug regulator -- Salerno is being given a shot at requesting a hearing if it wants to argue why the approval should not be withdrawn.

Salerno's simvastatin suspension was previously manufactured for Rosemont Pharmaceuticals, a Perrigo company.

Oral suspension atorvastatin (Atorvaliq) is an alternative liquid statin on the market.

来源:MedPage Today · medpagetoday.com